๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Ovarian Cancer Recurrent

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi NCT05551208Phase 21 site๐Ÿ“ Chongqing Chongqing University Cancer Hospital ยท Tests: fluzopanib and bevacizumab A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies NCT05803018Phase 1, Phase 21 site๐Ÿ“ Shanghai Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-B01D1 Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers NCT03564340Phase 1, Phase 254 sites๐Ÿ“ Birmingham๐Ÿ“ Boston๐Ÿ“ Boston Regeneron Pharmaceuticals ยท Tests: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy NCT07144826EARLY Phase 11 site๐Ÿ“ Columbus Ohio State University Comprehensive Cancer Center ยท Tests: Biospecimen Collection, Placebo Administration, Probiotic, Questionnaire Administration A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer NCT06840002Phase 1, Phase 21 site๐Ÿ“ Wuhan Suzhou Suncadia Biopharmaceuticals Co., Ltd. ยท Tests: SHR-A1811, Carboplatin, Bevacizumab, Oxaliplatin for Injection, Paclitaxel injection Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors NCT06646627Phase 11 site๐Ÿ“ Palo Alto Stanford University ยท Tests: B7-H3CART A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles๐Ÿ“ Whittier Daiichi Sankyo ยท Tests: Ifinatamab deruxtecan RC48 in Combination With AK104 and Bevacizumab in OCCC NCT06540729Phase 21 site๐Ÿ“ Guanzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovโ€ฆ A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. NCT07389239Phase 1, Phase 21 site๐Ÿ“ Chicago University of Chicago ยท Tests: Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFฮฒRII, Aldesleukin A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks NCT07469709n/a1 site๐Ÿ“ Candiolo Fondazione del Piemonte per l'Oncologia Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer NCT04518501Phase 1, Phase 21 site๐Ÿ“ Zhejiang Xing Xie ยท Tests: Arsenic trioxide Tablet +Fuzuloparib Capsules Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer NCT06040970Phase 1, Phase 21 site๐Ÿ“ New York Icahn School of Medicine at Mount Sinai ยท Tests: Sacituzumab, Cisplatin Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. NCT05753826Phase 21 site๐Ÿ“ Fujian Fujian Cancer Hospital ยท Tests: Adebrelimab, Fuzuloparib Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer NCT07564141Phase 39 sites๐Ÿ“ Duarte๐Ÿ“ Danbury๐Ÿ“ Tigard Genmab ยท Tests: Rina-S, Bevacizumab, Carboplatin, Gemcitabine, Paclitaxel MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer NCT06483048Phase 11 site๐Ÿ“ Scottsdale Mayo Clinic ยท Tests: Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. NCT06660511EARLY Phase 11 site๐Ÿ“ Changsha Second Xiangya Hospital of Central South University ยท Tests: Disitamab Vedotin in Combination With Anlotinib Hydrochloride Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer NCT05113368Phase 21 site๐Ÿ“ Cleveland Sarah K. Lynam MD ยท Tests: Regorafenib, Fulvestrant To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer NCT07651124NA1 site๐Ÿ“ Gyeonggi-do Yong Wha Moon ยท Tests: autologous tumor-infiltrating lymphocytes Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies NCT05457595NA1 site๐Ÿ“ Pavia CNAO National Center of Oncological Hadrontherapy ยท Tests: carbon ion radiation therapy Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study NCT07311577Phase 22 sites๐Ÿ“ Nanjing๐Ÿ“ Nanjing Jiangsu Cancer Institute & Hospital ยท Tests: RC48+Carboplatin+Bevacizumab Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer NCT06463028Phase 218 sites๐Ÿ“ La Jolla๐Ÿ“ San Francisco๐Ÿ“ Miami Beach Faeth Therapeutics ยท Tests: Sapanisertib, Serabelisib, Paclitaxel A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors NCT06769152Phase 21 site๐Ÿ“ Ji'nan Shanghai Henlius Biotech ยท Tests: HLX43 Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer NCT07718854Phase 21 site๐Ÿ“ Boston Tufts Medical Center ยท Tests: Sacituzumab tirumotecan, Pembrolizumab A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069Phase 139 sites๐Ÿ“ Duarte๐Ÿ“ La Jolla๐Ÿ“ Los Angeles Eli Lilly and Company ยท Tests: LY4052031, Pembrolizumab Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer NCT07171528Phase 21 site๐Ÿ“ Goyang-si National Cancer Center, Korea ยท Tests: Secondary Cytoreductive Surgery Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma NCT05112601Phase 2138 sites๐Ÿ“ Birmingham๐Ÿ“ Athens๐Ÿ“ Augusta National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence NCT06430541Phase 12 sites๐Ÿ“ Aurora๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: Psilocybin Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib NCT03651206Phase 2, Phase 336 sites๐Ÿ“ Angers๐Ÿ“ Besanรงon๐Ÿ“ Bordeaux ARCAGY/ GINECO GROUP ยท Tests: Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression NCT06839144Phase 22 sites๐Ÿ“ Ramat Gan๐Ÿ“ Tel Aviv Tel-Aviv Sourasky Medical Center ยท Tests: Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor), Placebo (Matching for Propranolol & Etodolac) Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells NCT06305299Phase 11 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: iC9-CAR.B7-H3 T cells, Cyclophosphamide, Fludarabine
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy